February 20, 2017
Mereo BioPharma’s rare bone disease drug to develop sooner
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: osteogenesis imperfecta
December 12, 2016
Mereo balance sheet strong, sufficient funds for clinical tests
Mereo BioPharma Group, a clinical stage, UK-based biopharmaceutical company focused on rare diseases, is looking to strengthen its rare and specialty disease…